Broad-spectrum kinase inhibitor.
Product Details
| Alternative Name: | N-[4-Chloro-3-(trifluoromethyl)phenyl]-([4-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl]amino)-carboxamide, Sorafenib |
| |
| Formula: | C21H16ClF3N4O3 |
| |
| MW: | 464.8 |
| |
| Source: | Synthetic. |
| |
| CAS: | 284461-73-0 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Identity determined by 1H-NMR. |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO, 100% ethanol, methanol or ethyl acetate. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells: K. Kim, et al.; Exp. Dermatol.
31, 57 (2022),
Application(s): Pigmentation studies on HM3KO melanoma cells,
Abstract;
Small molecule inhibitors of the mitochondrial ClpXP protease possess cytostatic potential and re-sensitize chemo-resistant cancers: M. Meßner, et al.; Sci. Rep.
11, 11185 (2021),
Abstract;
Full Text
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma: M. Mebner, et al.; FASEB J.
34, 11860 (2020),
Abstract;
Full Text
The kinase inhibitor Sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress: M. Rahmani, et al.; Mol. Cell. Biol.
27, 5499 (2007),
Abstract;
Sorafenib (BAY 43-9006, Nexavar((R))), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature: L. Adnane, et al.; Meth. Enzymol.
407, 597 (2005),
Abstract;
